Down-regulation of FoxM1 leads to the inhibition of the epithelial-mesenchymal transition in gastric cancer cells

Cancer Genetics

Volumn 207, Issue 3, 2014, Pages 75-82

  Miao, Lifeng ^a   Xiong, Xianze ^a   Lin, Yixin ^a   Cheng, Yao ^a   Lu, Jiong ^a   Zhang, Jie ^a   Cheng, Nansheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; FoxM1; Invasion; Migration

Indexed keywords

EPITHELIAL-MESENCHYMAL TRANSITION; FOXM1; INVASION; MIGRATION;

CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; GENE SILENCING; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 84899111392     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.02.008     Document Type: Article

References (27)

1. Mosavi-Jarrahi A., Mohagheghi M.A. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev 2006, 7:375-380.
2. Johnson S.M., Evers B.M. Translational research in gastric malignancy. Surg Oncol Clin N Am 2008, 17:323-340. viii.
3. Zheng L., Wang L., Ajani J., et al. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004, 7:61-77.
4. Kong D., Li Y., Wang Z., et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?. Cancers (Basel) 2011, 3:716-729.
5. Lim L., Michael M., Mann G.B., et al. Adjuvant therapy in gastric cancer. JClin Oncol 2005, 23:6220-6232.
6. De Vita F., Vecchione L., Galizia G., et al. Perspectives in adjuvant therapy of gastric cancer. Oncology 2009, 77(Suppl 1):38-42.
7. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277.
8. Shen H., Sun T., Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012, 19:367-373.
9. Xiong J., Sun W.J., Wang W.F., et al. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012, 118:536-548.
10. Wang Z., Ahmad A., Li Y., et al. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 2010, 36:151-156.
11. Laoukili J., Kooistra M.R., Brás A., et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005, 7:126-136.
12. Laoukili J., Stahl M., Medema R.H. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007, 1775:92-102.
13. Kalin T.V., Wang I.C., Ackerson T.J., et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006, 66:1712-1720.
14. Li Q., Zhang N., Jia Z., et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 2009, 69:3501-3509.
15. Feng Y., Wang L., Zeng J., et al. Fox M1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res 2013, 11:834-844.
16. Zeng J., Wang L., Li Q., et al. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. JPathol 2009, 218:419-427.
17. Ali S., Ahmad A., Banerjee S., et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010, 70:3606-3617.
18. Kawahira K. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res 1999, 291:413-418.
19. Keese C.R., Wegener J., Walker S.R., et al. Electrical wound-healing assay for cells invitro. Proc Natl Acad Sci U S A 2004, 101:1554-1559.
20. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8:843-852.
21. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829.
22. Desmoulière A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int 1995, 19:471-476.
23. Wang Z., Li Y., Ahmad A., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010, 13:109-118.
24. Katoh M., Igarashi M., Fukuda H., et al. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013, 328:198-206.
25. Leung T.W., Lin S.S., Tsang A.C., et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 2001, 507:59-66.
26. Balli D., Ustiyan V., Zhang Y., et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J 2013, 32:231-244.
27. Sato S., Yokozaki H., Yasui W., et al. Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn J Cancer Res 1999, 90:485-489.